Safety and efficacy of sofosbuvir plus ribavirin with or without pegylated interferon in predominant genotype 3 patients with chronic hepatitis-C : A real world experience

Trial Profile

Safety and efficacy of sofosbuvir plus ribavirin with or without pegylated interferon in predominant genotype 3 patients with chronic hepatitis-C : A real world experience

Completed
Phase of Trial: Phase II

Latest Information Update: 25 Oct 2016

At a glance

  • Drugs Ribavirin (Primary) ; Sofosbuvir (Primary) ; Peginterferon alfa-2a; Peginterferon alfa-2b
  • Indications Hepatitis C
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 25 Oct 2016 New trial record
    • 14 Sep 2016 Results published in the Journal of Gastroenterology and Hepatology
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top